.
Matchland Pty Ltd, (trading as New Products Development) and Granules India Limited are pleased to announce the signing of an Outsourcing Agreement where New Products Development agrees to outsource its finished dosage manufacturing requirement to Granules India for the Australian market.
Initially five products have been identified for manufacturing and this list is expected to grow as the relationship progresses. The agreement is in the nature of the partnership where New Products Development will compensate Granules for all the costs incurred in connection with the manufacture of the product and provide a transparent profit margin. This would be New Products Development’s first Outsourcing Agreement with any Indian Company and complements Granules strategy of expansion into lesser explored markets like Australia and New Zealand.

Commenting on the deal, Mr.C.Krishna Prasad, Managing Director said, we are planning to use our TGA approved pilot manufacturing capabilities to kickstart the manufacturing as soon as possible.

About New Products Development Established in 1988, New Products Development has grown to become a major provider in the pharmaceutical contract manufacturing industry, and is licensed by the Therapeutic Goods Administration (TGA) to manufacture non-sterile therapeutic goods for human use. New Products Development is an independent contract manufacturer with the capacity and capability to manufacture and pack unscheduled medicinal products in tablet, capsule and powder dosage form.

About Granules India Ltd
(BSE: 532482, NSE: GRANULES, Reuters: GRAN.BO)
Granules India Ltd. is a fully integrated pharmaceutical formulations manufacturer with the world's largest 'granulation' capacity. The company manufactures several strategic Active Pharmaceutical Ingredients (APIs) and multiple Pharmaceutical Formulation Intermediates (PFIs), which are distributed in 35 countries. It is foraying into manufacturing of tablets with a capacity of 6 billion tablets per annum. This facility will strengthen its presence in the pharma outsourcing space as it will have capabilities of offering a wide range of products beginning from APIs to finished dosages (coated/uncoated).

For further details please contact:

Granules India
Mrs.N.Madhavi
Cell: 91 98663 20405

Adfactors PR Pvt. Ltd; Mumbai
Rakesh Sharma/ Shalaka Parab
Phone: 022- 22813565
Email: rakesh@adfactorspr.com / shalaka@adfactorspr.com